SPECIAL REPORT: The Launches of Opsumit, Adempas, and Orenitram into the Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) is a severe and debilitating disease, with rapid disease progression and high rates of mortality. As a consequence, the necessity for effective treatments are increasingly required in order to alleviate patient symptoms and increase both quality and duration of life.

Contact sales account_box

Report

Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

Pulmonary hypertension (PH) is a high-burden condition with significant unmet needs across the major markets. Despite its small patient pool, the commercial potential for PH therapies is…

north_east

Report

Hypertension – Unmet Need – Unmet Need – Resistant Hypertension (US/EU)

Resistant hypertension (RHTN) has become a critical focus within the cardiovascular market because a substantial proportion of patients remain uncontrolled despite multidrug therapy, with…

north_east

Report

Hypertension – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertension (US)

Hypertension remains the most prevalent and clinically significant modifiable risk factor for cardiovascular disease. Treatment typically begins with firstline therapies centered around…

north_east

Report

Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…

north_east

Report

Hypertension – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of hypertension includes epidemiological estimates for key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each…

north_east

Product logins

SPECIAL REPORT: The Launches of Opsumit, Adempas, and Orenitram into the Pulmonary Arterial Hypertension Market

Related Market Assessment Reports

Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

Hypertension – Unmet Need – Unmet Need – Resistant Hypertension (US/EU)

Hypertension – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertension (US)

Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)

Hypertension – Epidemiology – Mature Markets

Follow us

Contact us